Spotlight

Insights

ObesityWeek Presentation: Additional P2a Study Data

Obesity specialist Louis Aronne, MD, highlights CB1 inhibitor weight loss, weight rebound (after therapy discontinuation) and waist circumference in new data from Skye’s CBeyond trial.

Released November 7, 2025

CBeyond P2a Data: Nimacimab as Mono and Combination Therapy

Phase 2a topline data highlights nimacimab as monotherapy and a combo with a GLP-1 therapeutic, semaglutide, with weight loss, tolerability and safety outcomes.

Released October 6, 2025

Nimacimab P1b Safety and Tolerability Data

Skye presents a summary of safety, tolerability, and pharmacokinetic data from the Phase 1b of nimacimab at diabetes/obesity conference.

Released September 19, 2025

Review: Preclinical Data and Unmet Needs for Obesity Therapeutics

Skye’s CEO and CMO get perspectives from three obesity specialists regarding new preclinical results and imminent CBeyond Phase 2a clinical trial data.

Released September 5, 2025

Reviewing Component Mechanisms of Peripheral CB1 Inhibitor Antibody

Skye’s CMO and CSO discuss key differentiating mechanistic components of its peripherally-restricted CB1-inhibiting antibody, nimacimab.

Released September 4, 2025

Comparing Weight Loss/Rebound between Distinct CB1 Inhibitors

Preclinical data assesses weight loss and rebound of peripheral CB1-inhibiting antibody, nimacimab, versus small molecule CB1 inhibitor, monlunabant.

Released September 4, 2025

Assessing Additive Effects when Combined with Tirzepatide

Data highlighting combination of nimacimab and suboptimal tirzepatide versus either drug alone in terms of weight loss, rebound and maintenance.

Released September 4, 2025

Assessing Nimacimab + Incretin Combination Weight Loss Dynamics

This research showed that nimacimab-driven weight loss is not a result of caloric deficit alone (via pair-fed study), as well as incremental weight rebound and maintenance benefits.

Released September 4, 2025

A Look at Manufacturing Nimacimab

Skye's COO discusses FDA requirements and considerations around manufacturing a monoclonal antibody such as nimacimab.

Released September 1, 2025